英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
blennius查看　blennius　在百度字典中的解释百度英翻中〔查看〕
blennius查看　blennius　在Google字典中的解释Google英翻中〔查看〕
blennius查看　blennius　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • PROVENGE (sipuleucel-T) | FDA
    Indication: For the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer
  • DailyMed - PROVENGE- sipuleucel-t injection
    PROVENGE ® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer
  • Provenge (sipuleucel-T)
    This policy evaluates whether the drug therapy is proven to be effective based on published evidence-based medicine OncoHealth reserves the right to request medical documentation as needed to validate medical necessity determinations
  • Sipuleucel-t Monograph for Professionals - Drugs. com
    It is essential that the manufacturer's labeling be consulted for more detailed information on usual uses, dosage and administration, cautions, precautions, contraindications, potential drug interactions, laboratory test interferences, and acute toxicity
  • PROVENGE 5. 6 Product Safety Testing - PROVENGE (sipuleucel-T)
    PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer
  • Sipuleucel-T - NCI - National Cancer Institute
    FDA label information for this drug is available at DailyMed Sipuleucel-T is approved to treat: Prostate cancer that has metastasized (spread to other parts of the body) It is used in men who have few or no symptoms and whose cancer is hormone-refractory (does not respond to hormone treatment)
  • Provenge® (sipuleucel-T) - OHSU
    Referenced with permission from the NCCN Drugs Biologics Compendium (NCCN Compendium®) for Sipuleucel-T National Comprehensive Cancer Network, 2025 The NCCN Compendium® is a derivative work of the NCCN Guidelines®
  • Provenge (sipuleucel-T) - CVS Caremark
    The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy
  • PROVENGE® (sipuleucel-T) for Healthcare Providers
    PROVENGE is the first FDA-approved immunotherapy using the patient’s own immune system to fight advanced prostate cancer Clinical studies have shown that PROVENGE extends life for certain men with mCRPC 3
  • Provenge: Package Insert Prescribing Information MOA
    Upon receipt, open the outer cardboard shipping box to verify the product and patient-specific labels located on the top of the insulated container Do not remove the insulated container from the shipping box, or open the lid of the insulated container, until the patient is ready for infusion





中文字典-英文字典  2005-2009